NuVasive — Merger or Acquisition (April 2023)
42 slides from NuVasive's merger presentation, Apr 4, 2023
Slide 1: Delivering compelling shareholder value: NuVasive's combination with Globus Medical
Exhibit 99.1 Delivering compelling shareholder value: NuVasive’s combination with Globus Medical April 2023 1 ©2023. NuVasive, Inc. or one of its subsidiaries. All rights reserved.
Slide 2: Safe harbor statements: Cautionary notes on forward-looking statements
Safe harbor statements Cautionary notes on forward-looking statements This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, a
Slide 3: Safe harbor statements: Important information about the transaction
Safe harbor statements Important information about the transaction and where to find it This communication relates to a proposed business combination of Globus Medical and NuVasive. In connection with the proposed transaction, Globus Medical filed a registration statement on Form S-4 with the SEC on
Slide 4: Agenda
Agenda • Executive summary • NuVasive’s journey of innovation • Combination with Globus Medical: Deep strategic rationale • Compelling value for NuVasive shareholders • Offer is attractive and in line with precedents • A rigorous process led by NuVasive’s independent, highly experienced Board 4 ©202
Slide 5: Executive summary
Executive summary 5 ©2023. NuVasive, Inc. or one of its subsidiaries. All rights reserved.
Slide 6: Executive summary
Executive summary Proposed transaction with Globus Medical delivers a unique and compelling opportunity for NuVasive shareholders • Combines two of the leading innovators in spine to target $50 billion musculoskeletal market opportunity Accelerates and strengthens our strategy • Pairs Globus Medical
Slide 7: Transaction overview
Executive summary Transaction overview Structure • Stock-for-stock merger • NuVasive shareholders will receive a fixed exchange ratio of 0.75 Globus Medical’s shares for each NuVasive share Anticipated Post- • Globus Medical shareholders: 72% Closing Ownership • NuVasive shareholders: 28% Governance
Slide 8: NuVasive's journey of innovation
NuVasive’s journey of innovation 8 ©2023. NuVasive, Inc. or one of its subsidiaries. All rights reserved.
Slide 9: Back pain is a growing, global problem
NuVasive’s journey of innovation Back pain is a growing, global problem Global population 60 years and 1.4 billion older—expected to double by 2050 Lower back pain affects 540 million 1 in 10 people globally Costs of annual treatment and $560+ billion loss of productivity in the U.S. alone Back pain
Slide 10: NuVasive's growth has been driven by innovation
NuVasive’s journey of innovation NuVasive’s growth has been driven by innovation Focused on introducing advanced technologies in spine and specialized orthopedics Expanding into new spine and orthopedic segments to drive above-market growth Pursuing globalization through expansion of portfolio into
Slide 11: Introducing advanced technologies to compete more broadly
NuVasive’s journey of innovation Introducing advanced technologies to compete more broadly Expanding the NUVA portfolio in Core Spine surgery Investing outside of through the introduction of innovative procedural solutions traditional spine surgery Specialized Orthopedics Anterior Cervical Magnetic
Slide 12: Globalization is a core focus
NuVasive’s journey of innovation Globalization is a core focus ~$280 million in 2022 net sales from outside the U.S. Global presence in 50+ countries 25+ office locations Surgeon education centers in San Diego, New Jersey, and Singapore Multiple regional distribution centers across the globe, includ
Slide 13: NuVasive's strategy focuses on growth and expansion
NuVasive’s journey of innovation NuVasive’s strategy focuses on growth and expansion NUVA Today Expansion Potential Continue momentum in the core business: Extend presence in lateral to greater share in other core spine segments (e.g., cervical) Globalize the business: Expand reach and breadth of po
Slide 14: Standalone strategy requires significant investment and scale to achieve potential
NuVasive’s journey of innovation Standalone strategy requires significant investment and scale to achieve potential Drivers of Potential Requirements to achieve potential Continue momentum Extending strength in lateral to other Dependent on comprehensive and core segments (cervical, anterior) differ
Slide 15: Combination with Globus Medical: Deep strategic rationale
Combination with Globus Medical: Deep strategic rationale 15 ©2023. NuVasive, Inc. or one of its subsidiaries. All rights reserved.
Slide 16: Combining with Globus Medical greatly accelerates NuVasive's standalone strategy
Deep strategic rationale Combining with Globus Medical greatly accelerates NuVasive’s standalone strategy Requirements under standalone plan How combination delivers Continue momentum Dependent on comprehensive and Comprehensive suite of best-in-class differentiated portfolio to fully compete techno
Slide 17: Globus Medical is a highly regarded spine and orthopedics leader
Deep strategic rationale Globus Medical is a highly regarded spine and orthopedics leader Focused on developing innovative solutions across the continuum of care Pioneer in expandables and robotics Consistent share-taker driven by innovation Strong financial profile and operational rigor $1.0 billio
Slide 18: Globus Medical's exceptional performance is recognized and rewarded by investors
Deep strategic rationale Globus Medical’s exceptional performance is Stock Price Performance 5-Year 3-Year 1-Year recognized and rewarded by investors GMED 77.7% 44.3% 10.9% NUVA (0.5%) (39.7%) (10.5%) 1 (21.5%) (24.9%) (25.8%) Spine Peers GMED +10.9% NUVA (10.5%) Spine Peers (25.8%) Source: FactSet
Slide 19: Continue momentum in the core business
Deep strategic rationale – continue momentum in the core business Globus NuVasive Combination creates a broad and competitive spine portfolio with little commercial overlap Simplify cervical disc NuVasive ACP system ® Quartex • Combination brings together a number of Fixation System MAGEC system com
Slide 20: Accelerates globalization strategies to win in high-value markets
Deep strategic rationale – globalize the business Accelerates globalization strategies to win in high-value markets Combined presence in over 50 countries, with more than $400 million in combined 2022 net sales Complementary international footprint in key markets incl. Japan, Australia/New Zealand,
Slide 21: De-risks and accelerates Intelligent Surgery vision
Deep strategic rationale – invest in intelligent surgery De-risks and accelerates Intelligent Surgery vision Pre-op Intra-op Post-op Patient assessment Procedure selection Procedure execution Healing & recovery Outcome evaluation & optimization & planning & verification monitoring & continual learni
Slide 22: Scale orthopedics
Deep strategic rationale – scale orthopedics Globus NuVasive ® ANTHEM Small Fragment Fracture Combination greatly advances System ® CAPTIVATE ® Compression ANTHEM Screw System Mini Fragment orthopedic portfolio and brings Fracture System ® ANTHEM ® ANTHEM Clavicle Fracture scale to a key growth vect
Slide 23: Improves operational efficiencies
Deep strategic rationale – operational efficiencies Improves operational efficiencies Combination unlocks manufacturing capacity and increases asset utilization to drive meaningful operational efficiencies Further vertical integration supported by strong third-party vendor partners allows for scale
Slide 24: Benefits of scale for shareholders of the combined company
Deep strategic rationale – benefits of scale Combination provides rapid and valuable scale for the benefit of shareholders of the combined company Greater scale - 2022A ~$2 billion in a $50 billion market $1.2 billion in a $13 billion addressable market Net Sales Expanding presence in underpenetrate
Slide 25: Customer and industry perspectives
Deep strategic rationale – customer and industry perspectives Customers and industry executives see the value of combining NuVasive and Globus Medical Surgeon Customers Industry Executives Survey “The Globus-NuVasive merger expands patient and surgeon “Spine-focused deal with little overlap and comp
Slide 26: Wall Street perspectives
Deep strategic rationale – Wall Street perspectives Wall Street research analysts recognize the strategic merits of the combination March 19, 2023 February 23, 2023 Combined Company Better Positioned to Compete Integration Risks Mitigated by Direct Salesforce “… with a combined portfolio and increas
Slide 27: Compelling value for NuVasive shareholders
Compelling value for NuVasive shareholders 27 ©2023. NuVasive, Inc. or one of its subsidiaries. All rights reserved.
Slide 28: Standalone vs. pro forma combined company
Compelling value for NuVasive shareholders Standalone vs. pro forma combined company Combined company is larger, faster growing, and more profitable than standalone Standalone Pro Forma Combined NOTE: Standalone NUVA Revenue Pro Forma Combined Revenue NUVA Standalone $3,224 CAGR: 7.3% $3,009 $2,776
Slide 29: Experienced integration team pursuing significant synergy potential
Compelling value for NuVasive shareholders Experienced integration team pursuing significant synergy potential An experienced integrations team… Confident in capturing synergies… To achieve a shared mission • Established Integration Management • High degree of confidence in achieving • Primary share
Slide 30: Investors recognize Globus Medical's exceptional performance
Compelling value for NuVasive shareholders Investors recognize Globus Medical’s exceptional performance Historical NTM P/E • Globus Medical’s stock price has traded above NuVasive’s stock price in the past few years • An all-equity transaction allows GMED NuVasive shareholders to benefit 32.4x in th
Slide 31: Significant value upside based on strength of combined company
Compelling value for NuVasive shareholders Significant value upside based on strength of combined company operating profile Based on P/E Value Creation Analysis – $ per share NuVasive’s share of the combined company will result in significant value creation $111.24 opportunity for NuVasive sharehold
Slide 32: Offer is attractive and in line with precedents
Offer is attractive and in line with precedents 32 ©2023. NuVasive, Inc. or one of its subsidiaries. All rights reserved.
Slide 33: Transaction multiple consistent with precedent transactions
Offer is attractive and in line with precedents Transaction multiple consistent with other selected precedent spine / orthopedic M&A transactions 1 Transaction Value / LTM EBITDA 26.0x 2 Transaction Multiple at Announcement: 13.7x Median Transaction Multiple: 12.3x 16.4x 11.7x 11.3x 12.3x 4/27/11 2/
Slide 34: Premium to unaffected trading level and current price
Offer is attractive and in line with precedents Premium to unaffected trading level and premium to current price NuVasive Share Price $65.00 $57.72/Share 26% Premium Implied Over Unaffected $60.00 2 Consideration at Share Price 1 Announcement $55.00 $50.00 Precedent premiums paid analysis for all-st
Slide 35: Market reaction to the transaction likely overstated and short-term
Offer is attractive and in line with precedents Market reaction to the transaction likely overstated and short-term Share Price Performance Since Transaction Overview Announcement • We believe the market reaction to the transaction is likely transitory o Short-term reaction from all-equity nature of
Slide 36: A rigorous process led by NuVasive's independent Board
A rigorous process led by NuVasive’s independent, highly experienced Board 36 ©2023. NuVasive, Inc. or one of its subsidiaries. All rights reserved.
Slide 37: Process overview
A rigorous process led by NuVasive’s independent, highly experienced Board Process overview The NuVasive Board met 10+ times from December 2022 - February 2023 with management and the company’s financial and legal advisors to discuss the proposed combination and to evaluate alternatives for maximizi
Slide 38: World-class, independent board of directors
A rigorous process led by NuVasive’s independent, highly experienced Board World-class, highly qualified, independent board of directors focused on delivering shareholder value Chris Barry Daniel Wolterman Vickie Capps Robert Friel John DeFord Chief Executive Officer Independent Chair Independent Di
Slide 39: Board is committed to good governance practices
A rigorous process led by NuVasive’s independent, highly experienced Board NuVasive’s Board is committed to good governance practices Accountability and Independence of NuVasive’s Board Governance Highlights Independent directors meet frequently Directors elected by majority vote in executive sessio
Slide 40: Thoughtful, robust and deliberate process
A rigorous process led by NuVasive’s independent, highly experienced Board NuVasive conducted thoughtful, robust and deliberate process Early discussions in September 2021 with negotiations Active involvement by independent and experienced in earnest starting in early December 2022 Board, led by ind
Slide 41: Favorable deal terms
A rigorous process led by NuVasive’s independent, highly experienced Board Favorable deal terms • Exchange Ratio resulting in ~28% ownership in the combined company Share of the • Opportunity for NuVasive shareholders to participate in a higher margin and faster growing pro forma combined company vs
Slide 42: Key takeaways
Key takeaways Proposed transaction with Globus Medical delivers a unique and compelling opportunity for NuVasive shareholders • Combines two of the leading innovators in spine to target $50 billion musculoskeletal market opportunity Accelerates and strengthens • Pairs Globus Medical’s and NuVasive’s